Overview

The Gene Technology Act 2000 was enacted to address the need for a regulatory framework governing the development and use of genetically modified organisms (GMOs) in Australia, aiming to ensure these activities do not adversely affect human health, safety, or the environment. The Act was introduced by the Parliament of Australia to establish a robust system for the assessment and oversight of GMOs, reflecting the policy objective of balancing innovation in biotechnology with the protection of public welfare and ecological integrity. In this context, the Office of the Gene Technology Regulator is responsible for managing the regulatory process, including the assessment of applications for field trials of genetically modified organisms. The Regulator is currently reviewing an application from the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to conduct a field trial of genetically modified canola designed to enhance tolerance to abiotic stress. The proposed trial, which excludes the use of the modified canola for food or feed, involves multiple sites over several years, with a focus on gathering data to evaluate potential risks to human health and the environment. Public submissions on this application are welcomed and should be submitted by 23 August 2024, referencing DIR 205, to inform the Regulator's decision on whether to grant the necessary licence for the trial.

Scope and Application

The C2024G00420 Gazette, pertaining to DIR 205, outlines the assessment process for a proposed field trial of genetically modified canola conducted by the Commonwealth Scientific and Industrial Research Organisation (CSIRO). This trial, intended to enhance the plant's resistance to abiotic stresses, is geographically limited to New South Wales and South Australia. The scope of the legislation applies directly to the entities involved in the application and trial process, including CSIRO and potentially other stakeholders who may submit written submissions as part of the consultation period. The Act specifically addresses the protection of human health and safety, as well as environmental concerns, and does not extend to the use of the genetically modified canola for human food or animal feed purposes. The geographic reach of this legislation is confined to the states mentioned, aligning with national regulations under the Gene Technology Act 2000. While the primary focus is on the proposed trial, the legislation also accommodates the potential extension or restriction of application through subordinate instruments as deemed necessary by the Gene Technology Regulator. The consultation period, ending on 23 August 2024, invites relevant submissions to ensure comprehensive evaluation before a decision on issuing the licence is made.

Key Provisions

The key provisions of the legislation outlined in C2024G00420 concern an application by CSIRO to conduct a field trial of genetically modified canola designed to enhance tolerance to abiotic stress (section 1). The proposed trial is intended to be conducted at up to three sites, each covering an area of up to 6 hectares annually, over a period of six years. The locations for these trials are specified to be in New South Wales and South Wales. Importantly, the canola produced in these trials will not be intended for human consumption or animal feed (section 2). The Gene Technology Regulator has prepared a comprehensive Risk Assessment and Risk Management Plan (RARMP) to address potential risks to human health, safety, and the environment. This document is integral to the decision-making process regarding the issuance of a licence for the trial. The Regulator has made this RARMP, along with related information, accessible to the public via their website or through direct contact. The obligations imposed by this legislation on the parties involved are primarily centred around the submission of written comments regarding the RARMP. Any individual or entity wishing to provide feedback must ensure that their submissions reference DIR 205 and are submitted by 23 August 2024. This deadline is critical for the Regulator to consider all relevant input before making a decision on the trial licence. Furthermore, the Regulator has specified the necessary contact details, including a website, email address, and telephone number, to facilitate the submission process. While the legislation does not explicitly outline specific offences, penalties, or civil/criminal consequences for non-compliance, the overarching framework of the Gene Technology Act 2000, under which this trial operates, does provide for such measures. Non-compliance with the provisions of the Act or the conditions of any licence issued can result in significant penalties, including fines and imprisonment. The exact penalties are determined by the severity of the breach and are detailed within the broader legislative context provided by the Gene Technology Act. The Regulator’s decision to issue or withhold a licence is also influenced by the feedback and risk assessments presented, underscoring the importance of adhering to the submission guidelines.